Effect of valsartan on postprandial plasma inflammatory factors in patients with essential hypertension

Journal of Central South University (Medical Sciences)

Volumn 33, Issue 9, 2008, Pages 809-813

  Liu, Ling ^a   Zhao, Shui Ping ^a   Zhou, Hong Nian ^a   Xu, Dan Yan ^a   Li, Ji Xiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

High fat meal; High sensitivity C reactive protein; Hypertension; P selectin; Valsartan

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; DRUG DERIVATIVE; PADGEM PROTEIN; TETRAZOLE DERIVATIVE; TRIACYLGLYCEROL; VALINE; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FAT INTAKE; FEMALE; HUMAN; HYPERTENSION; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; C-REACTIVE PROTEIN; DIETARY FATS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; P-SELECTIN; TETRAZOLES; TRIGLYCERIDES; VALINE;

EID: 53649107303     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. LIU Ling, ZHAO Shui-ping, ZHOU Hong-nian, et al. Effect of fluvastatin on plasma triglyceride and P-selectin af ter a high-fat meal[J]. Chin J Hypertens, 2005, 13 (1): 14-17.
2. LIU Ling, ZHAO Shui-ping, LI Quan-zhong, et al. Influence of fluvastatin on postprandial high-sensitivity C-reactive protein concentrations in patients at high risk of cardiovascular event[J]. Chin J Cardiol, 2004, 32 (7): 603-605.
3. LIU Ling, ZHAO Shui-ping, CHENG Yan-chun, et al. Optimal time point to measure postprandial hypertriglyceridemia after a high-fat meal[J]. Chin J Endocrinol Metab, 2004, 20 (1): 23-25.
4. Liu L, Zhao S P, Gao M, et al. Vitamin C preserves endothelial function in patients with coronary heart disease after a high-fat meal[J]. Clin Cardiol, 2002, 25 (5): 219-224.
5. Sanada H, Midorikawa S, Yatabe J, et al. Elevation of serum soluble E- and P-selectin in patients with hypertension is reversed by benidipine, a long-acting calcium channel blocker[J]. Hypertens Res, 2005, 28 (11): 871-878.
6. Nadar S, Blann A D, Lip G Y. Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy[J]. Ann Med, 2004, 36 (7): 552-557.
7. Wassmann S, Hilgers S, Laufs U, et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction[J]. Arterioscler Thromb Vasc Biol, 2002, 22 (7): 1208-1212.
8. Tomiyama H, Yambe M, Yamada J, et al. Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication[J]. J Hypertens, 2007, 25 (4): 883-889.
9. XIE Qi-ying, WANF Yong-jin, SUN Ze-lin, et al. Effects of valsartan and indapamide on plasma cytokines in essential hypertension[J]. J Cent South Univ (Med Sci), 2006, 31 (5): 629-634.
10. Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action[J]. J Clin Endocrinol Metab, 2003, 88 (9): 4496-4501.
11. Manabe S, Okura T, Watanabe S, et al. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension[J]. J Cardiovasc Pharmacol, 2005, 46 (6): 735-739.
12. Serebruany V L, Pokov A N, Malinin A I, et al. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan inhibits platelets (VIP) trial[J]. Am Heart J, 2006, 151 (1): 92-99.